Get started
Author

Susanna Kim

ORCID: 0009-0009-3066-2447
Observed ORCID: 0009-0009-3066-2447
OpenAlex ID: A5081298081
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma
2022 · James R. Berenson, Daisy Martinez, et al. · British Journal of Haematology · 11
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
2022 · Marissa-Skye Goldwater, Samuel D. Stampfer, et al. · Clinical Infection in Practice · 10
PDF
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients
2023 · Scott Jew, Sean Bujarski, et al. · Targeted Oncology · 8
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen
2022 · Jonathan Afari, Tanya M. Spektor, et al. · Experimental Hematology · 5
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
2024 · James R. Berenson, Andrea Limon, et al. · Targeted Oncology · 3
Predicting outcomes and monitoring disease in patients with multiple myeloma.
2023 · Susanna Kim, James R Berenson · PubMed · 3
When Does the Reproduction of Violence Begin? The Effects of Indirect Violence during Clinical Training on Career Identity
2024 · Eun-Hi Choi, Ji-yeon Kim, et al. · SAGE Open · 2
Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective study
2023 · Bernard Sean Regidor, Scott Jew, et al. · European Journal Of Haematology · 2
PDF
Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma
2022 · James R. Berenson, Daisy Martinez, et al. · Blood · 2
Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody
2022 · Bernard Sean Regidor, Dilawer Siddiqi, et al. · European Journal Of Haematology · 2
Medical writing bias in myeloma clinical research: A comprehensive analysis
2024 · Adam ElSayed, Sarah Mettias, et al. · Perspectives in Clinical Research · 1
A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone
2023 · James R Berenson, Andrea Limon, et al. · Blood · 1
PDF
Medical Writing Bias in Myeloma Clinical Research: A Comprehensive Analysis
2023 · Adam ElSayed, Sarah Mettias, et al. · Blood
PDF
The Adiponectin Pathway Regulates ERRα Activity to Modulate Mitochondrial Gene Expression and Metabolism in Skeletal Myocytes
2020 · Angelica Hamilton, Susanna Kim, et al. · The FASEB Journal
Works count: 14
Citation count: 50
H-index: 4
I10-index: 2
Year
Topic
Type